Publication: The predictive usefulness of the novel "combined hemoglobin-to-platelet ratio and maximum mouth opening index" on prevalence of radiation induced trismus in patients with nasopharyngeal cancer
dc.contributor.coauthor | Somay, Efsun | |
dc.contributor.coauthor | Yilmaz, Busra | |
dc.contributor.coauthor | Topkan, Erkan | |
dc.contributor.coauthor | Kucuk, Ahmet | |
dc.contributor.coauthor | Pehlivan, Berrin | |
dc.contributor.department | School of Medicine | |
dc.contributor.kuauthor | Selek, Uğur | |
dc.contributor.schoolcollegeinstitute | SCHOOL OF MEDICINE | |
dc.date.accessioned | 2024-12-29T09:40:25Z | |
dc.date.issued | 2023 | |
dc.description.abstract | Objectives: To explore how well a unique combination of hemoglobin-to-platelet ratio (HPR) and pretreatment maximum mouth opening (MMO) predicts the prevalence of radiation-induced trismus (RIT). Patients and methods: HPR and MMO cutoff values (0.54 and 40.7 mm) divided patients into two groups. To develop the novel HPR-MMO index, four combinations of these factors were tested for predictive power: Group 1: HPR > 0.54 and MMO > 40.7 mm; Group 2: HPR <= 0.54 but MMO > 40.7 mm; Group 3: HPR > 0.54 but MMO <= 40.7 mm; Group 4: HPR <= 0.54 and MMO <= 40.7 mm. Results: Data of 198 patients with LA-NPC was analyzed retrospectively. RIT rates for Groups 1 to 4 were 10.2%, 15.2%, 25%, and 59.4%. Groups 2 and 3 were merged to generate HPR-MMO index because of statistically equivalent RIT rates: Low-risk: HPR > 0.54 and MMO > 40.7 mm; Intermediate-risk: HPR <= 0.54 but MMO > 40.7 mm or; HPR > 0.54 but MMO <= 40.7 mm; High-risk: HPR <= 0.54 and MMO <= 40.7 mm. It was revealed that the low-, high-, and intermediate-risk group's RIT rates; 10.2%, 59.4%, and 19.2%, respectively. Conclusion: The novel HPR-MMO index may to classify LA-NPC patients into low, intermediate, and high-risk RIT groups. | |
dc.description.indexedby | WOS | |
dc.description.indexedby | Scopus | |
dc.description.indexedby | PubMed | |
dc.description.issue | 7 | |
dc.description.publisherscope | International | |
dc.description.sponsoredbyTubitakEu | N/A | |
dc.description.volume | 45 | |
dc.identifier.doi | 10.1002/hed.27400 | |
dc.identifier.eissn | 1097-0347 | |
dc.identifier.issn | 1043-3074 | |
dc.identifier.quartile | Q1 | |
dc.identifier.scopus | 2-s2.0-85159053410 | |
dc.identifier.uri | https://doi.org/10.1002/hed.27400 | |
dc.identifier.uri | https://hdl.handle.net/20.500.14288/23312 | |
dc.identifier.wos | 986348300001 | |
dc.keywords | Biomarker | |
dc.keywords | Concurrent chemoradiotherapy | |
dc.keywords | Hemoglobin-to-platelet ratio | |
dc.keywords | Nasopharyngeal cancer | |
dc.keywords | Trismus | |
dc.language.iso | eng | |
dc.publisher | Wiley | |
dc.relation.ispartof | Head and Neck-Journal for the Sciences and Specialties of the Head and Neck | |
dc.subject | Otorhinolaryngology | |
dc.subject | Surgery | |
dc.title | The predictive usefulness of the novel "combined hemoglobin-to-platelet ratio and maximum mouth opening index" on prevalence of radiation induced trismus in patients with nasopharyngeal cancer | |
dc.type | Journal Article | |
dspace.entity.type | Publication | |
local.contributor.kuauthor | Selek, Uğur | |
local.publication.orgunit1 | SCHOOL OF MEDICINE | |
local.publication.orgunit2 | School of Medicine | |
relation.isOrgUnitOfPublication | d02929e1-2a70-44f0-ae17-7819f587bedd | |
relation.isOrgUnitOfPublication.latestForDiscovery | d02929e1-2a70-44f0-ae17-7819f587bedd | |
relation.isParentOrgUnitOfPublication | 17f2dc8e-6e54-4fa8-b5e0-d6415123a93e | |
relation.isParentOrgUnitOfPublication.latestForDiscovery | 17f2dc8e-6e54-4fa8-b5e0-d6415123a93e |